Abstract
The question why some individuals and not others get idiopathic Parkinson’s disease, which involves a selective degeneration of dopamine-containing cells in the substantia nigra, is still unanswered. The disease incidence in identical twins has shown no higher concordance than between random members of the population (Ward et al., 1983). The pattern of incidence has remained reasonably constant over time, and although there is some population clustering, it is insufficient to point to a clear environmental cause (Schoenberg, 1987). Other epidemiological findings amount to little. There is some evidence for an inverse relationship between smoking and Parkinson’s disease (Tanner et al., 1987), but the reason for this finding is unclear.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Barbeau, A., Cloutier, T., Roy, M. et al., (1985) Ecogenetics of Parkinson’s disease: 4-hydroxylation of debrisoquine. Lancet, ii, 1213–16.
Birkmayer, W., Knoll, J., Riederer, P. et al. (1985) Increased life expectancy resulting from addition of 1-deprenyl to madopar treatment in Parkinson’s disease: a long term study. J. Neural Transm., 64, 113–27.
Birkmayer, W., Riederer, P., Youdim, M.B.H. and Linauer, W. (1975) Potential of antiakinetic effect after L-dopa treatment by an inhibitor of MAO B, 1-deprenyl. J. Neural Transm., 36, 303–23.
Burns, R.S., Chiueh, C.C., Markey, S.P. et al. (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine.Proc. Natl. Acad. Sci, USA, 80, 4546–550.
Calne, D.B. and Peppard, R.F. (1987) Aging of the nigrostriatal pathway in humans. Can. J. Neurol. Sci., 14, 424–7.
Cohen, G., Pasik, P., Cohen, B. et al. (1985) Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur. J. Pharmacol .106, 209–10.
D’Amato, R.J., Lipman, Z.P. and Snyder, S.H. (1986) Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. Science, 231,987–9.
Danielczyk, M., Streifler, M., Konradi, C. et al. (1988) Platelet MAO-B activity and the psychopathology of Parkinson’s disease, senile dementia and multi-infarct dementia.Acta Psychiatr. Scand., 78, 730–6.
Davis, G.C., Williams, A.C., Markey, S.P. et al, (1979) Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatr. Res., 1, 249–54.
Di Monte, D., Shinka, T., Sandy, M.S. et al. (1988) Quantitative analysis of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine metabolism in isolated rat hepatocytes. Drug Metab. Dispos., 16, 250–5.
Elsworth, J.D., Glover, V., Reynolds, G.P. et al. (1978) Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the ‘cheese effect’. Psychopharmacology (Berlin), 57, 33–8.
Gibb, C, Willoughby, J., Glover, V. et al. (1987) Analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as monoamine oxidase substrates: a second ring is not necessary. Neurosci. Lett., 76, 316–22.
Glover, V., Elsworth, J.D. and Sandler, M. (1980) Dopamine oxidation and its inhibition by (-)deprenyl in man. J. Neural Transm. (Suppl), 16, 163–72.
Glover, V., Gibb, C. and Sandler, M. (1986) Monoamine oxidase B (MAO B) is the major catalyst of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) oxidation in human brain and other tissues. Neurosci. Lett.,64, 216–20.
Glover, V., Halket, J.M., Watkins, P.J. et al. (1988) Isatin: identity with the purified endogenous monoamine oxidase inhibitor tribulin. J. Neurochem., 51, 656–9.
Glover, V., Lees, A.J., Ward, C. et al. (1983) Platelet phenolsulphotransferase activity in Parkinson’s disease. J. Neural Transm., 57, 95–102.
Glover, V., Sandler, M., Owen, F. and Riley, G.J. (1977) Dopamine is a monoamine oxidase B substrate in man. Nature, 265, 80–1.
Heikkila, R.E., Manzino, L., Cabbat, F.S. and Duvoisin, R.C. (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetra-hydropyridine by monoamine oxidase inhibitors. Nature, 311, 467–9.
Heikkila, R.E., Kindt, M.V., Sonsalla, P.K. et al. (1988) Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA, 85, 6172–6.
Jaritch, J.A., d’Amato, R.J., Strittmatter, S.M. and Snyder, S.H. (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine: uptake of the metabolite N-methyl-4-phenylpyridinium by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Aci. USA, 82, 2173–7.
Knoll, J. (1988) The striatal dopamine dependency of life span in male rats: longevity study with (-)deprenyl. Mech. Ageing Dev., 46, 237–62.
Kopin, I.J. and Markey, S.P. (1988) MPTP toxicity: implications for research in Parkinson’s disease. Ann. Rev. Neurosci., 11, 81–96.
Langston, J.W. (1988) Neuromelanin-containing neurons are selectively vulnerable in parkinsonism. Trends Pharmacol. Sci., 9, 347–8.
Langston, J.W. and Irwin, I. (1989) Pyridine toxins in Drugs for the Treatment of Parkinson’s Disease (ed. D.B. Calne) Springer-Verlag, New York, pp. 205–26.
Littlewood, J.T., Glover, V., Sandler, M. et al. (1984) Migraine and cluster headache: links between platelet monoamine oxidase activity, smoking and personality. Headache, 24, 30–4.
Naoi, M., Matsuura, S., Takahashi, T. and Nagatsu, T. (1989) A N-methyl-transferase in human brain catalyses N-methylation of 1,2,3,4-tetrahydro-isoquinoline into N-methyl-1,2,3,4-tetrahydroisoquinoline, a precursor of a dopaminergic neurotoxin, N-methylisoquinolinium ion. Biochem. Biophys. Res. Commun., 161, 1213–19.
Niwa, T., Takeda, N., Kaneda, N. et al. (1987) Presence of etrahydroisoquinoline and 2-methyl-tetrahydroquinoline in parkinsonian and normal human brains. Biochem. Biophys. Res. Commun., 144, 1084–9.
Ogawa, M., Araki, M., Nagatsu, I. et al. (1989) The effect of 1,2,3,4-tetrahydro-isoquinoline (TIQ) on mesencephalic dopaminergic neurons in C57BL/6J mice: immunohistochemical studies—tyrosine hydroxylase. Biogenic Amines, 6,427–36.
Riederer, P. and Youdim, M.B.H. (1986) Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with 1-deprenyl. J. Neurochem., 46, 1359–65.
Salach, J.I., Singer, T.P., Castagnoli, N. Jr. and Trevor, A. (1984) Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP Biochem. Biophys. Res. Commun., 125,831–5.
Sandler, M. and Glover, V. (1989) Monoamine oxidase inhibitors in Parkinson’s disease, in Drugs for the Treatment of Parkinson s Disease (ed. D.B. Calne), Springer-Verlag, New York, pp. 411–31.
Schapira, A.H.V., Cooper, J.M., Dexter, D. et al. (1989) Mitochondrial complex 1 deficiency in Parkinson’s disease. Lancet, i, 1269.
Schoenberg, B.S. (1987) Environmental risk factors for Parkinson’s disease: the epidemiologic evidence. Can. J. Neurol. Sci., 14,407–13.
Sonsalla, P.K. and Heikkila, R.E. (1988) Neurotoxic effects of 1-methyi-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and methamphetamine in several strains of mice. Prog. Neuropsychopharmacol. Biol. Psychiatr .12, 345–54.
Strolin Benedetti, M. and Dostert, P. (1989) Monoamine oxidase, brain ageing and degenerative diseases. Biochem. Pharmacol., 38, 555–61.
Tanner, CM., Chen, B., Wange, W.-Z. et al. (1987) Environmental factors in the etiology of Parkinson’s disease. Can. J. Neurol. Sci.,14, 419–23.
Tetrud, J.W. and Langston, J.W. (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science, 245, 519–22.
Ward, CD., Duvoisin, R.C and Ince, S.E. (1983) Parkinson’s disease in 65 pairs of twins and in a set of quadruplets. Neurology, 33, 815–25.
Westlund, K.N., Denney, R.M., Kochersperger, L.M. et al. (1985) Distinct monoamine oxidase A and B populations in primate brain. Science,230, 181–3.
Willoughby, J., Cowburn, R.F., Hardy, J.A. et al. (1989) 1-Methyl-4-phenyl-pyridinium uptake by human and rat striatal synaptosomes. J. Neurochem., 52, 627–31.
Willoughby, J., Glover, V. and Sandler, M. (1988a) Histochemical localisation of monoamine oxidase A and B in rat brain. J. Neural Transm., 74, 29–42.
Willoughby, J., Glover, V., Sandler, M. et al. (1988b) Monoamine oxidase activity and distribution in marmoset brain: implications for MPTP toxicity. Neurosci. Lett., 90, 100–6.
Yahr, M.D. and Kaufmann, H. (1989) Clinical actions of L-deprenyl in Parkinson’s disease, in Drugs for the Treatment of Parkinson s Disease, (ed. D.B. Calne), Springer-Verlag, New York, pp. 411–31.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Glover, V., Sandler, M. (1991). Monoamine oxidase-mediated activation of MPTP and related compounds. In: Hlavica, P., Damani, L.A. (eds) N-Oxidation of Drugs. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-3112-4_21
Download citation
DOI: https://doi.org/10.1007/978-94-011-3112-4_21
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-5378-5
Online ISBN: 978-94-011-3112-4
eBook Packages: Springer Book Archive